Ocular gout is defined by which pathological process?

Calcium pyrophosphate deposition in the corneal stroma

Immune complex deposition along the retinal vessels

Amyloid fibril accumulation in the conjunctival stroma

Why are ocular tissues vulnerable to urate crystal precipitation in gout?

They contain avascular zones and fluid compartments Persistent hyperuricaemia supersaturates monosodium urate, and the eye's avascular zones and fluid compartments provide sites where those crystals can precipitate.

They receive the highest blood flow of any tissue

They lack lymphatic drainage in the posterior pole

They run at a higher temperature than nearby tissue

How does ocular gout cause secondary glaucoma?

Urate crystals block outflow at the trabecular meshwork Urate deposits in the trabecular meshwork obstruct aqueous outflow, raising intraocular pressure and producing a secondary glaucoma.

Crystals push the lens forward and close the angle

A steroid response follows long-term systemic gout therapy

A neovascular membrane grows across the iris surface

What proportion of adults in developed countries is affected by systemic gout?

1% to 2% Systemic gout affects 1-2% of adults in developed countries, yet ocular involvement remains rare and probably underreported because of misdiagnosis.

Which patients are most likely to develop ocular gout?

Men over 50 with longstanding uncontrolled gout Ocular gout primarily affects men over 50 who have longstanding uncontrolled disease, particularly those with visible tophaceous deposits.

Premenopausal women with newly diagnosed gout

Children with inherited purine enzyme deficiencies

Patients within weeks of a first acute gout attack

How do conjunctival tophi appear on slit-lamp examination in ocular gout?

Chalky white nodules that can mimic a pinguecula Urate deposits in the conjunctiva and sclera form chalky white nodules resembling subconjunctival tophi, which are easily mistaken for a pinguecula.

Vascularised pink nodules sitting at the limbus

Translucent cysts filled with clear watery fluid

Flat pigmented lesions spreading onto the cornea

Which mediator drives the inflammatory tissue damage in ocular gout?

Interleukin-1 beta released after neutrophil activation Inflammation in ocular gout is driven by neutrophil activation with release of interleukin-1 beta, together with oxidative stress that worsens tissue damage.

Vascular endothelial growth factor from ischaemic retina

Immunoglobulin E released by conjunctival mast cells

Complement C1q deposited along Bruch membrane

Which investigation helps visualise corneal urate crystals in ocular gout?

Anterior segment OCT or confocal microscopy Anterior segment OCT and confocal microscopy allow direct visualisation of the crystalline deposits, supporting slit-lamp documentation and a raised serum uric acid.

Fundus fluorescein angiography of both eyes

Full-field electroretinography under scotopic conditions

B-scan ultrasonography of the posterior segment

Which systemic drug class is central to the treatment of ocular gout?

Urate-lowering agents such as allopurinol or febuxostat Systemic control rests on urate-lowering therapy with allopurinol, febuxostat or uricosurics, supported by topical steroids and antiglaucoma drops as needed.

Long-term oral tetracycline antibiotics

Systemic carbonic anhydrase inhibitors taken indefinitely

Weekly low-dose methotrexate with folate supplementation

What is the consequence of delayed diagnosis in ocular gout?

Chronic keratopathy, persistent glaucoma and vision loss With early recognition and control of hyperuricaemia the deposits may regress, but delay leads to chronic keratopathy, persistent glaucoma and irreversible visual loss.

Deposits calcify and become inert without visual effect

Permanent proptosis with marked upper lid retraction

Retinal detachment develops in the majority of patients

Ocular Gout and Uric Acid Crystal Deposition

Case Study

A 60-year-old man with a 20-year history of gout and multiple tophaceous deposits in his extremities presented with worsening eye irritation, blurred vision, and halos around lights.

He had recently discontinued urate-lowering therapy due to poor compliance. On examination, slit-lamp evaluation revealed needle-shaped crystalline deposits in the corneal periphery and anterior chamber, along with conjunctival hyperemia and mild anterior uveitis.

Intraocular pressure was elevated at 28 mmHg, suggesting secondary glaucoma. Funduscopy showed no posterior segment involvement, but optical coherence tomography (OCT) revealed subtle irregularities in the corneal layers.

Laboratory tests confirmed serum uric acid levels of 11.2 mg/dL. The patient was diagnosed with ocular gout, and systemic as well as topical therapy was initiated to control inflammation and intraocular pressure.

Disease Entity

Ocular gout is an uncommon but clinically significant manifestation of systemic gout, defined by uric acid crystal deposition in various ocular structures.

While most cases of gout affect joints, tophaceous urate deposition in the eye can mimic other ophthalmic diseases, often leading to diagnostic delay.

Recognizing this rare entity is essential, as untreated cases can progress to vision-threatening complications.

Test your knowledge 10 questions from this article

Pathophysiology

Ocular gout arises from persistent hyperuricemia, resulting in supersaturation of monosodium urate and subsequent crystal deposition.

The eye is vulnerable due to avascular zones and fluid compartments where crystals can precipitate. Deposits are most frequently seen in:

Cornea – stromal infiltration leading to opacification and visual impairment.
Conjunctiva and sclera – chalky white nodules resembling subconjunctival tophi.
Anterior chamber – free-floating or precipitated crystals, sometimes inducing anterior uveitis.
Trabecular meshwork – blockage of aqueous humor outflow, causing secondary glaucoma.
Rare sites – retina, choroid, and lens, where deposits may compromise vascular supply or induce inflammatory changes.

Inflammation is driven by neutrophil activation, release of interleukin-1β, and oxidative stress, which together worsen ocular tissue damage.

Epidemiology

Although systemic gout affects 1–2% of adults in developed countries, ocular involvement remains rare and underreported.

It primarily affects men over 50 with longstanding uncontrolled gout, particularly those with visible tophaceous deposits.

The true prevalence may be underestimated due to a lack of awareness and misdiagnosis as uveitis, keratitis, or conjunctival lesions.

Clinical Features

Ocular gout may present with a spectrum of manifestations, including:

Recurrent eye redness and irritation
Foreign body sensation and photophobia
Blurred vision or reduced visual acuity
Halos around lights due to corneal edema
Visible crystalline deposits in the conjunctiva, sclera, or cornea
Signs of secondary glaucoma (elevated IOP, optic disc cupping)
Anterior uveitis–like inflammation

Examination Findings

Slit-lamp: white or needle-shaped crystalline deposits in cornea, conjunctiva, sclera, or anterior chamber
Conjunctival tophi: chalky nodules, sometimes mimicking pinguecula
IOP: often elevated due to trabecular obstruction
Anterior chamber: inflammatory cells, flare, and crystals
Posterior segment: usually spared, though rare reports describe retinal ischemia or urate deposition

Differential Diagnosis

Band keratopathy
Corneal dystrophies (lattice, granular)
Calcific conjunctival deposits
Ocular amyloidosis
Chronic anterior uveitis of other etiologies

Diagnosis

Diagnosis relies on a combination of systemic history and ophthalmic examination. Supporting tools include:

Serum uric acid measurement (typically elevated)
Slit-lamp documentation of crystalline deposits
Anterior segment OCT or confocal microscopy for crystal visualization
Histopathological confirmation in excised lesions (rarely needed)

Management

Treatment of ocular gout requires systemic and local approaches:

Systemic therapy: urate-lowering medications (allopurinol, febuxostat, uricosurics) and anti-inflammatory agents for acute gout attacks.
Topical therapy: corticosteroid drops for inflammation, antiglaucoma medications if IOP is elevated.
Surgical intervention: excision of conjunctival tophi or glaucoma surgery in refractory cases.
Lifestyle modification: a diet low in purines, hydration, and avoidance of alcohol and certain medications.

Prognosis

The prognosis depends on early recognition and systemic control of hyperuricemia. With proper treatment, ocular deposits may regress, and inflammation subsides.

However, delayed diagnosis can lead to chronic keratopathy, persistent glaucoma, and irreversible visual loss.

Prevention

Preventive strategies include:

Long-term urate-lowering therapy in patients with chronic gout
Regular monitoring of serum uric acid
Periodic ophthalmic screening in patients with severe tophaceous gout
Patient education on adherence and lifestyle modification

References

Fraunfelder FW. Ocular manifestations of gout. Am J Ophthalmol. 1990.
Bhosle D, et al. Ocular urate deposits: A rare presentation of gout. Indian J Ophthalmol. 2014.
Dalbeth N, et al. Pathophysiology of hyperuricemia and gout. Lancet. 2016.
Kuo C, et al. Gout and the eye: A review. Surv Ophthalmol. 2020.

Test yourself

A few questions straight from this article.

1 / 10 0 correct

Ocular gout is defined by which pathological process?
Ocular gout is an uncommon manifestation of systemic gout defined by uric acid crystal deposition in ocular structures, and it frequently mimics other ophthalmic diseases.
Why are ocular tissues vulnerable to urate crystal precipitation in gout?
Persistent hyperuricaemia supersaturates monosodium urate, and the eye's avascular zones and fluid compartments provide sites where those crystals can precipitate.
How does ocular gout cause secondary glaucoma?
Urate deposits in the trabecular meshwork obstruct aqueous outflow, raising intraocular pressure and producing a secondary glaucoma.
What proportion of adults in developed countries is affected by systemic gout?
Systemic gout affects 1-2% of adults in developed countries, yet ocular involvement remains rare and probably underreported because of misdiagnosis.
Which patients are most likely to develop ocular gout?
Ocular gout primarily affects men over 50 who have longstanding uncontrolled disease, particularly those with visible tophaceous deposits.
How do conjunctival tophi appear on slit-lamp examination in ocular gout?
Urate deposits in the conjunctiva and sclera form chalky white nodules resembling subconjunctival tophi, which are easily mistaken for a pinguecula.
Which mediator drives the inflammatory tissue damage in ocular gout?
Inflammation in ocular gout is driven by neutrophil activation with release of interleukin-1 beta, together with oxidative stress that worsens tissue damage.
Which investigation helps visualise corneal urate crystals in ocular gout?
Anterior segment OCT and confocal microscopy allow direct visualisation of the crystalline deposits, supporting slit-lamp documentation and a raised serum uric acid.
Which systemic drug class is central to the treatment of ocular gout?
Systemic control rests on urate-lowering therapy with allopurinol, febuxostat or uricosurics, supported by topical steroids and antiglaucoma drops as needed.
What is the consequence of delayed diagnosis in ocular gout?
With early recognition and control of hyperuricaemia the deposits may regress, but delay leads to chronic keratopathy, persistent glaucoma and irreversible visual loss.